Published online April 1, 2008
PEDIATRICS Vol. 121 No. 4 April 2008, pp. 831-832 (doi:10.1542/peds.2008-0068)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benjamin, D. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benjamin, D. K., Jr
Related Collections
Right arrow Infectious Disease & Immunity
Right arrowRelated AAP Red Book topics:
Fungal Diseases
Candidiasis (Moniliasis, Thrush)
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

COMMENTARY

First, Do No Harm

Daniel K. Benjamin, Jr, MD, PhD, MPH

Department of Pediatrics, Duke University, Duke Clinical Research Institute, Durham, North Carolina

The first 20% of the full text of this article appears below.

Healy et al1 are to be commended for their continued study of fluconazole resistance, one of the potential negative effects of systemic antifungal prophylaxis. In this issue of Pediatrics, the authors provide modest new evidence to support fluconazole use, provided that we first correctly investigate the risks and benefits of fluconazole prophylaxis.

All drugs cause harm to at least a small proportion of children who receive them. Some drugs reduce or cure disease in children, and very few drugs benefit more children than are harmed by their use. The pressing public health concern regarding the adoption of fluconazole prophylaxis hinges on this risk/benefit ratio. Although antifungal prophylaxis has reduced candidiasis in the high-incidence setting, some questions remain unanswered by investigators (1) Does prophylaxis reduce neonatal mortality?, (2) Is prophylaxis . . . [Full Text of this Article]

Address correspondence to Daniel K. Benjamin, Jr, MD, PhD, MPH, Department of Pediatrics, Duke University, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715. E-mail: danny.benjamin@duke.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 PediatricsHome page
D. Kaufman
Fluconazole Prophylaxis Decreases the Combined Outcome of Invasive Candida Infections or Mortality in Preterm Infants
Pediatrics, November 1, 2008; 122(5): 1158 - 1159.
[Full Text] [PDF]